Aptamer Therapeutics Limited, part of Aptamer Group, is pleased to announce a new collaboration with the University of Manchester and Cancer Research UK
Online PR News – 02-May-2019 – York – Following the successful awarding of a CRUK Biotherapeutic Drug Discovery Project Award, Aptamer Therapeutics Limited, part of Aptamer Group, is pleased to announce a new collaboration with Dan Wiseman and the Oglesby Leukaemia Research Programme at the University of Manchester and Cancer Research UK. The project will explore the potential of aptamers as therapeutic agents for the treatment of Chronic Myelomonocytic Leukaemia (CMML) and other myeloid malignancies.
Aptamers are synthetic alternatives to antibodies that can be designed as therapeutics to disrupt disease targets and pathways.
The partnership intends to build on the initial data showing aptamers with therapeutic potential that can selectively target a key gene fault involved in driving this group of cancers.
Tony Hickson, Cancer Research UK's chief business officer, said: "We're thrilled to support this collaboration, building on excellence in drug discovery at the Cancer Research UK Manchester Institute. By bringing together the best minds in academic cancer research with the rigour and drive of industry partners, we can accelerate the development of potentially life-saving new treatments."
The Cancer Research UK Biotherapeutic Drug Discovery Project Award aims to increase the availability of biotherapeutic drugs for the management of cancer. Aptamers are a relatively young technology, and this will allow the assessment of their potential in a wider therapeutic setting.
Arron Tolley, Aptamer Therapeutics' Chief Executive Officer, said: "We are excited to partner with Cancer Research UK and the University of Manchester. This is further validation of the potential of our platform to generate therapeutic molecules for further development."
About Aptamer Therapeutics
Aptamer Therapeutics is part of Aptamer Group Ltd - a UK-based biotechnology company developing aptamers, nucleic acid molecules with affinity and selectivity for a specified target, as an alternative to antibodies. Aptamer Group is recognised as a key player in the aptamer selection market; offering customers access to an accelerated aptamer selection platform that delivers tailor-made high-affinity, highly specific molecules for use in a variety of scenarios. For more information, visit https://www.aptamergroup.co.uk/therapeutics/
For more information, contact: Katie Lockwood, Operations Manager, firstname.lastname@example.org, tel: + 44 (0)1904 567 790. Aptamer Group, Suite 2.78 - 2.91, Bio Centre, Innovation Way, Heslington, York, YO10 5NY
For more press information, contact Louise Reid, The Scott Partnership: email@example.com, tel: + 44 (0)1477 539539, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA.
Sent from: The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, CW4 8AA